Recently, emerging evidence supports an important role of systemic inflammation in the pathobiology of soft tissue sarcomas, with several studies reporting prognostic implications of inflammatory biomarkers such as serum cytokines8, C-reactive protein (CRP)9, erythrocyte sedimentation rate (ESR)10, as well as alterations in specific subsets of circulating peripheral blood cells. This evidence concerns the gene CRP and soft tissue sarcoma.